Rachel King assumed the leadership of the Biotechnology Innovation Organization (BIO) as CEO on November 1, 2022. Mrs. King is co-founder and former CEO of GlycoMimetics, Inc. (GMI). Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis.
She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. Mrs. King now serves on the boards of GlycoMimetics, Inc., Novavax, Inc. and the University of Maryland BioPark. She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School.